KOSDAQBiotech & Pharma115180

Qurient

₩13,160▲ 0.08%2026-11-18 close
Market Cap
₩493.9B
Turnover
₩2.4B
Volume
180K
Shares out.
37.5M
PER
—
PBR
58.1×
EPS
-₩1,056
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Qurient: ADC Expansion Amid Persistent Losses

Qurient is directing more capital into its dual-payload ADC platform and clinical pipeline, yet its disclosed results show losses in every year from 2022 to 2025 and in each of the last five quarters.

  1. 1

    Revenue fell 23.9% to KRW 6.98 billion in 2025, while the operating loss widened to KRW 29.8 billion.

  2. 2

    The Q3 2026 operating loss narrowed to KRW 6.97 billion from KRW 12.8 billion in Q2, but the net loss attributable to controlling shareholders was wider than a year earlier.

  3. 3

    The debt-to-equity ratio rose to 58.2% at the end of 2025 from 10.2% a year earlier, with total equity of KRW 39.2 billion.

  4. 4

    A rights offering raising KRW 101.6 billion is under way, and the corrected disclosure sets the payment date for new shares at December 3, 2026.

  5. 5

    In ADC work, the company has a co-commercialization agreement with Lonza and has filed an international patent application for its dual-payload ADC platform.

02

Business structure

Qurient is a drug research and development company founded in July 2008 and listed on KOSDAQ in 2016. Its pipeline spans Q203 for drug-resistant tuberculosis, Q301 for atopic dermatitis and Q701 for immuno-oncology and resistant cancers.

Q203 has completed a Phase 1 study in the US, and Q301 has completed a Phase 2A study in the US. The company's current focus is antibody-drug conjugate (ADC) technology, where the CDK7 inhibitor Q901 has reported Phase 1 dose-escalation results and a first patient dosed in a proof-of-concept study in breast cancer.

Its dual-payload ADC, QP101, is under a co-commercialization agreement with the global CDMO Lonza, which presented the platform strategy at World ADC 2026. Qurient has also filed an international patent application (PCT) covering its dual-payload ADC platform technology.

The company describes its model as a 'Labless Research House', expanding development through external collaboration rather than in-house laboratories. Revenue of KRW 6.98 billion in 2025 is small, so the research-driven structure shows directly in its results. In the domestic ADC field it is grouped with peers such as LigaChem Biosciences and ABL Bio.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩1.7B-₩7B−415.4%
2025Q4₩1.5B-₩9.3B−606.2%
2026Q1₩1.9B-₩7.7B−394.8%
2026Q2₩1.9B-₩12.8B−672.7%
2026Q3₩1.7B-₩7B−398.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩8.5B-₩27.5B-₩25.5B−324.4%−82.2%9.3%
2023₩9B-₩23.2B-₩21.1B−257.0%−48.1%5.5%
2024₩9.2B-₩27.5B-₩24.1B−299.3%−48.1%10.2%
2025₩7B-₩29.8B-₩30.1B−426.3%−88.3%58.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-10

04

Earnings analysis

Annual revenue rose from KRW 8.47 billion in 2022 to KRW 9.03 billion in 2023 (up 6.7% year on year) and KRW 9.18 billion in 2024 (up 1.6%), then fell to KRW 6.98 billion in 2025 (down 23.9%). Among 2022 to 2025, 2024 was the largest year and 2025 the smallest.

Operating losses were KRW 27.5 billion in 2022, KRW 23.2 billion in 2023 (losses narrowed), KRW 27.5 billion in 2024 (losses widened) and KRW 29.8 billion in 2025 (losses widened), marking four consecutive years of losses from 2022 to 2025.

Operating margin was -324.4% in 2022, -257.0% in 2023, -299.3% in 2024 and -426.3% in 2025, so the loss ratio was highest in 2025, the year of smallest revenue.

Net loss attributable to controlling shareholders was KRW 25.5 billion in 2022, KRW 21.1 billion in 2023, KRW 24.1 billion in 2024 and KRW 30.1 billion in 2025, while the net loss including non-controlling interests was KRW 31.3 billion in 2025, a different measure.

Operating cash flow was -KRW 25 billion in 2022, -KRW 22 billion in 2023, -KRW 23.3 billion in 2024 and -KRW 28.7 billion in 2025, the largest outflow of the four years.

The debt-to-equity ratio rose to 58.2% at the end of 2025 from 10.2% in 2024; total equity was KRW 39.2 billion, of which KRW 34 billion belonged to controlling shareholders, and total liabilities were KRW 22.8 billion.

Quarterly revenue peaked at KRW 1.94 billion in the first quarter of 2026, then fell for two straight quarters to KRW 1.91 billion in Q2 and KRW 1.75 billion in Q3.

Quarterly operating losses were KRW 7.01 billion in Q3 2025, KRW 9.26 billion in Q4 2025, KRW 7.67 billion in Q1 2026, KRW 12.8 billion in Q2 2026 and KRW 6.97 billion in Q3 2026, widening in Q2 before narrowing in Q3.

In Q4 2025, according to third-party data, non-operating items swung to a large loss, pushing the net loss well beyond the operating loss.

The net loss attributable to controlling shareholders in Q3 2026 was KRW 6.71 billion, a wider loss than a year earlier, and the four-quarter total for the last four quarters was KRW 38.7 billion.

05

Industry analysis

ADC technology attaches a drug to an antibody so that it reaches cancer cells selectively, and indication expansion continues in oncology development. Recently, dual-payload structures that carry two drugs with different mechanisms on one antibody have been discussed as a next-generation direction.

This approach is described as an attempt to address the resistance problems that arise with single-payload drugs. Qurient is trying to extend this technology into a platform rather than a single candidate.

Lonza presenting the platform strategy at World ADC 2026 shows that an overseas contract developer is paying attention to the technology. Whether a licensing deal actually happens, and on what terms, will depend on clinical data and the partner's development priorities.

In Korea, listed ADC developers such as LigaChem Biosciences and ABL Bio compete in the same field. In biotech licensing, a platform's value is judged differently depending on whether it has entered the clinic and how much data it has.

Qurient's results still depend more on clinical and licensing progress than on commercial sales. Its R&D spending shows up directly in quarterly operating losses, so pipeline progress is also a driver of earnings swings.

06

Outlook

The nearest scheduled step the company has disclosed is the rights offering. The final issue price is expected to be set on November 20, 2026, and the corrected disclosure puts the payment date for new shares at December 3, 2026.

The company has said the proceeds will be focused on dual-payload ADC development and new target ADC programs. In the clinic, reports say Q901 has entered a proof-of-concept efficacy study in breast cancer, and Q301 has completed a Phase 2A study.

On licensing, reports mention a third-party technology transfer as early as this year, but no signed agreement has been confirmed. Fourth-quarter 2026 results have not yet appeared in a periodic report, so the next official figures will come with the 2026 annual report.

Quarterly operating losses have moved between the KRW 7 billion range and KRW 12.8 billion over recent quarters, making the pace of R&D spending the key variable. With operating cash outflow of KRW 28.7 billion in 2025, the annual report's cash flow lines will show how long the new capital can support research.

07

Valuation

PER
—
PBR
58.1×
ROE
-131.4%
EPS
-₩1,056
BPS
₩272
Dividend per share
₩0

Because the last four quarters show net losses, the price-to-earnings ratio cannot be calculated. The price-to-book ratio sits well above the industry average, which reads as a large premium over net asset value.

Total equity fell to KRW 39.2 billion at the end of 2025, while market capitalization remains far above book assets. That points to the market pricing pipeline and licensing potential rather than current assets. Whether this reading holds depends on clinical results and whether licensing agreements are signed.

The company pays no cash dividend, so its dividend yield is below the industry average. Without dividend income, shareholder value depends more heavily on business results and how the company raises capital.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-10

08

Bull factors

Dual-payload ADC platform

The company has a co-commercialization agreement with Lonza, which presented the platform strategy at World ADC 2026. An international patent application (PCT) has been filed, widening the intellectual property from a single candidate to a platform. If licensing is concluded, part of the development cost could be shared with an outside partner.

Quarterly loss narrowing

The Q3 2026 operating loss was KRW 6.97 billion, down from KRW 12.8 billion in Q2, and revenue rose 3.7% from a year earlier. Quarterly losses widened in Q2 before narrowing in Q3. Whether cost spending is being managed while revenue stays small is the next point to watch.

Secured capital route

After weighing options including private mezzanine financing, the company chose a rights offering of KRW 101.6 billion open to existing shareholders, according to its announcement. It said the visibility of clinical and business development progress is rising. If the proceeds go to dual-payload and new target ADC programs, pipeline expansion could speed up.

09

Bear factors

Four years of losses and loss scale

Qurient recorded four consecutive years of losses from 2022 to 2025, and the KRW 29.8 billion operating loss in 2025 was the largest of those years. The four-quarter total of net losses attributable to controlling shareholders reached KRW 38.7 billion.

With revenue falling to KRW 6.98 billion in 2025, the losses have continued without clear signs of improvement in reported profit.

Shift in financial structure

The debt-to-equity ratio climbed to 58.2% in 2025 from 10.2% in 2024, with total liabilities of KRW 22.8 billion on the balance sheet. Total equity fell to KRW 39.2 billion. Operating cash outflow of KRW 28.7 billion in 2025 was the largest of the four years.

Clinical risk and licensing uncertainty

With a thin revenue base, earnings depend on clinical results and the completion of licensing deals. If pipeline data disappoint, licensing terms and timing could turn less favorable. The Q2 2026 operating loss reaching KRW 12.8 billion coincided with heavier R&D spending, according to third-party data.

10

Risk factors

Clinical and regulatory

Qurient's pipeline, including Q901, Q301, Q203 and Q701, remains in clinical stages, and results could change the development path. Weak data from later-stage studies could delay licensing talks or lower terms. Additional regulatory requests could extend timelines and raise costs.

Funding and dilution

The rights offering plans to issue 7.1 million new shares to raise KRW 101.6 billion. The final issue price could change both the amount raised and the number of shares. If operating losses continue after the offering, further funding may be needed.

Revenue base and profitability

Revenue fell 23.9% in 2025, and quarterly revenue declined for two straight quarters in 2026. The operating margin of -426.3% in 2025 was the most negative of the four years. If revenue does not recover, margin improvement would depend largely on cost control.

11

What to watch next

  1. November 20, 2026

    The final issue price for the rights offering is expected to be set. This fixes the amount raised and the number of new shares, so the disclosure is worth checking.

  2. December 3, 2026

    The payment date for the new shares in the rights offering. It marks when the funds actually come in and their size becomes known.

  3. By end-2026 (possibly this year)

    Whether a third-party licensing deal is signed. If it is, the upfront payment, terms and external valuation of the dual-payload ADC platform will become visible.

  4. By end-March 2027

    The deadline for the 2026 annual report. Confirmed full-year revenue, operating loss and operating cash flow will appear, allowing comparison with the 2025 trend.

12

Overall view

On a disclosed basis, Qurient recorded four consecutive years of losses from 2022 to 2025, with revenue falling to KRW 6.98 billion and the operating loss widening to KRW 29.8 billion in 2025. In 2026, quarterly revenue fell for two straight quarters after peaking in Q1, and the Q3 operating loss narrowed from Q2.

The debt-to-equity ratio rose to 58.2% at the end of 2025, and total equity stands at KRW 39.2 billion. Supporting factors include the Lonza co-commercialization agreement, the international patent application for the dual-payload ADC platform, and development funding from the KRW 101.6 billion rights offering.

Offsetting factors include continued losses on a thin revenue base, a KRW 38.7 billion net loss attributable to controlling shareholders over the last four quarters, and uncertainty over clinical results and licensing timing.

With PER not calculable on four quarters of net losses and the price-to-book ratio at a large premium, the share price appears to reflect pipeline value more than assets.

The next checkpoints are the final issue price on November 20, 2026, the share payment on December 3, 2026, whether a licensing deal is signed this year, and the 2026 annual report by the end of March 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.fnguide.com
  2. thevc.kr
  3. k5.co.kr
  4. alphasquare.co.kr
  5. m.sedaily.com
  6. ssl.pstatic.net
  7. medipharmhealth.co.kr
  8. digitaltoday.co.kr
  9. google.com
  10. markets.hankyung.com
  11. kr.investing.com
  12. tradingkey.com
  13. tradingkey.com
  14. kr.investing.com
  15. prnewswire.com
  16. globenewswire.com
  17. kr.investing.com
  18. kr.investing.com

Report written 2026-11-11 · Data as of 2026-11-10

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis